The following article features coverage from the 2021 ASCO Quality Care Symposium. Click here to read more of Oncology Nurse Advisor‘s conference coverage.

The Building Out Lifelines for Safety, Trust, Empowerment, and Renewal (BOLSTER) intervention is a technology-enhanced, nurse-led care management program for patients with gynecologic cancers who were hospitalized for peritoneal carcinomatosis (PC). Pilot programs found the intervention to be feasible and acceptable. These findings were presented during the 2021 ASCO Quality Care Symposium.

PC affects most women with advanced gynecologic cancers. Many of these patients require catheters, gastric tubes, or ostomies that can be difficult for patients and their caregivers to manage after discharge. The BOLSTER program (ClinicalTrials.gov Identifier: NCT03367247) was developed to address the gaps in patient care.

A team of stakeholders and experts were assembled to develop patient- and family-centered educational resources in the form of printed materials and short videos. For nurses, they developed a protocolized manual that detailed care coordination, training, and symptom management strategies. In addition, a smartphone application was designed to assess patient-reported symptoms, deliver tailored educational content, and prompt clinical action.


Continue Reading

The researchers tested 2 iterations of the BOLSTER program to determine feasibility and acceptability of the program. Feasibility was defined as a consent-to-approach ratio of 50% or greater. Acceptability was defined as 70% or more of participants recommending the program.

The first pilot program included 4 patients, lasted 10 weeks, and comprised 12 nurse visits. Two of the patients declined home visits, 2 of the patients thought the program lasted too long, and 3 of the patients wished BOLSTER had started earlier in their disease course.

In response to this feedback, the program was shortened to 4 weeks, home visits were eliminated, and eligibility was expanded for the second pilot program.

The BOLSTER program was found to be feasible and acceptable. This study was limited by the small sample size, however, the study authors plan to conduct a randomized controlled study to confirm the feasibility and acceptability of the BOLSTER program.

Disclosure: This research was supported by US National Institutes of Health. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please refer to the original reference for a full list of authors’ disclosures.

Read more of Oncology Nurse Advisor’s coverage of the 2021 ASCO Quality Care Symposium by visiting the conference page.

Reference

Pozzar RA, Enzinger AC, Orechia M, et al. Building out lifelines for safety, trust, empowerment, and renewal: Development, feasibility, and acceptability of the BOLSTER intervention for patients with gynecologic cancers and their caregivers. J Clin Oncol. 2021;39(suppl 28):abstr 187. doi:10.1200/JCO.2020.39.28_suppl.187